Showing results (41-50 of 101) with videos related to
Sort By:
Pageof 11
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.Brain : a Journal of Neurology|November 30, 2022
Not all roads lead to the immune system: the genetic basis of multiple sclerosis severityVilija G Jokubaitis, Maria Pia Campagna, Omar Ibrahim, et al.Annals of Neurology|December 30, 2014
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisTomas Kalincik, Dana Horakova, Tim Spelman, et al.JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 7, 2014
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.Pageof 11